Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

China's Zhaoke Ophthalmology H1 revenue rises

China's Zhaoke Ophthalmology H1 revenue rises


Overview

  • China ophthalmic drug maker's interim revenue rose yr/yr to RMB 18.8 mln

  • Non-HKFRS adjusted loss for the period widened slightly to RMB 116.1 mln

  • Company advanced regulatory filings for key drugs and expanded global partnerships


Outlook

  • Company expects flagship products to progress through regulatory reviews in China and Australia

  • YUVEZZI has received regulatory approval in Hainan and Macau; commercialization sought in Greater Bay Area

  • Company expanding international footprint with partnerships in Singapore and Vietnam


Result Drivers

  • REGULATORY PROGRESS - Co advanced regulatory filings for flagship drug candidates in China and internationally

  • NEW DRUG APPROVALS - Co received regulatory approvals for presbyopia drug YUVEZZI in Hainan and Macau

  • INTERNATIONAL EXPANSION - Co expanded global partnerships and commercialization efforts in Singapore and Vietnam


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

RMB 18.83 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"


Reuters Recommended Reads

  • Aug 28 - China's Chaoju Eye Care H1 net profit falls on lower insurance pricing

  • Aug 26 - China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales

  • Aug 27 - China's CStone Pharmaceuticals H1 revenue soars on drug sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Zhaoke Ophthalmology

See all news